Respiratory Medicine Section, Department of Internal Medicine, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark.
Int J Mol Sci. 2020 Dec 28;22(1):205. doi: 10.3390/ijms22010205.
Acute respiratory distress syndrome (ARDS) is an acute inflammation of the lung resulting from damage to the alveolar-capillary membrane, and it is diagnosed using a combination of clinical and physiological variables. ARDS develops in approximately 10% of hospitalised patients with pneumonia and has a mortality rate of approximately 40%. Recent research has identified several biomarkers associated with ARDS pathophysiology, and these may be useful for diagnosing and monitoring ARDS. They may also highlight potential therapeutic targets. This review summarises our current understanding of those clinical biomarkers: (1) biomarkers of alveolar and bronchiolar injury, (2) biomarkers of endothelial damage and coagulation, and (3) biomarkers for treatment responses.
急性呼吸窘迫综合征（ARDS）是一种由肺泡-毛细血管膜损伤引起的肺部急性炎症，其诊断采用临床和生理学变量的组合。ARDS 约发生于住院肺炎患者的 10%，死亡率约为 40%。最近的研究确定了一些与 ARDS 病理生理学相关的生物标志物，这些标志物可能对 ARDS 的诊断和监测有用。它们还可能突出潜在的治疗靶点。这篇综述总结了我们目前对这些临床生物标志物的认识：（1）肺泡和细支气管损伤的生物标志物；（2）内皮损伤和凝血的生物标志物；（3）治疗反应的生物标志物。
Zotero 插件